Released May 7, 2020, after the close
10-Q filed May 11, 2020, 41 days after period end · 0001162194-20-000042
Q1 2020 · 10-Q
Revenue$27.62M$27.62M −8.3% vs Q1 2019−14.9% vs Q4 2019
Net Income-$15.98M-$15.98M N/M vs Q1 2019N/M vs Q4 2019
EPS Diluted-$0.23-$0.23 N/M vs Q1 2019N/M vs Q4 2019
Gross Profit$13,002,000−23.5%
Operating Income-$14,942,000N/M
Operating Cash Flow-$4,295,000N/M
Free Cash Flowderived-$5,325,000N/M
Margins · derived
Gross margin47.1%−9.3 pt vs Q1 2019
Operating margin-54.1%−6.9 pt vs Q1 2019
Net margin-57.9%+26.7 pt vs Q1 2019
What the release said
The release
Same quarter
| Metric | Q1 2020 | Q1 2019 | Q1 2018 | Q1 2017 |
|---|---|---|---|---|
| Revenue | $27.62M | $30.11M | $25.25M | $25.53M |
| Net Income | -$15.98M | -$25.47M | -$13.25M | -$17.20M |
| EPS Diluted | -$0.23 | -$0.44 | -$0.34 | -$0.59 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR